Journal of Surgery Concepts & Practice >

2023 , Vol. 28 >Issue 02: 124 - 131

DOI: https://doi.org/10.16139/j.1007-9610.2023.02.08

Guideline and consensus

The fifth edition of WHO classification of digestive system tumors: update and progress on biliary system tumors

Expand
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2023-03-22

  Online published: 2023-06-06

Fold

Abstract

Overall, there was little change in biliary system tumors of the 5th edition of WHO classification of digestive system tumors after update. The three-tiered classification of biliary intraepithelial neoplasia changed to two-tiered system: high-grade and low-grade, in the section of benign tumors and precancerous lesions. And both intracholecystic and intraductal papillary tumors associated with invasive carcinoma were added. The classification of intrahepatic bile duct tumors introduced parts of bile duct adenoma and bile duct adenofibroma, which were mentioned previously in the differential diagnosis with bile duct carcinoma. Intrahepatic cholangiocarcinoma was divided into small bile duct subtype and large bile duct subtype in the 5th edition of WHO classification, and the names of cholangiocellular carcinoma and cholangiole cell carcinoma were no longer recommended to use. Extrahepatic cholangiocarcinoma was listed as a separate part for the first time, including squamous cell carcinoma, adenosquamous carcinoma and undifferentiated carcinoma in addition to common histological types. Some new contents of molecular pathology in the 5th edition of WHO classification were added, which provided the basis for precise classification and diagnosis of tumors in biliary system.

Key words： Biliary system tumor; Pathological diagnosis; Tumor classification

Cite this article

LUO Fangxiu, MA Qianchen, YUAN Fei . The fifth edition of WHO classification of digestive system tumors: update and progress on biliary system tumors[J]. Journal of Surgery Concepts & Practice, 2023 , 28(02) : 124 -131 . DOI: 10.16139/j.1007-9610.2023.02.08

References

[1] The WHO Classification of Tumors Editorial Board. WHO classification of tumours of digestive system tumors[M]. 5th ed. Lyon:IARC press: 2019.
[2] GERAMIZADEH B. Precursor lesions of cholangiocarcinoma: a clinicopathologic review[J]. Clin Pathol, 2020, 13:2632010X20925045.
[3] ETTEL M, EZE O, XU R. Clinical and biological significance of precursor lesions of intrahepatic cholangiocarcinoma[J]. World J Hepatol, 2015, 7(25):2563-2570.
[4] HE C, FUKUMURA Y, TORIYAMA A, et al. Pyloric gland adenoma (PGA) of the gallbladder: a unique and distinct tumor from PGAs of the stomach, duodenum, and pancreas[J]. Am J Surg Pathol, 2018, 42(9):1237-1245.
[5] ADSAY V, JANG K T, ROA J C, et al. Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are ≥1.0 cm): clinicopathologic and immunohistochemical analysis of 123 cases[J]. Am J Surg Pathol, 2012, 36(9):1279-1301.
[6] ROCHA F G, LEE H, KATABI N, et al. Intraductal pa-pillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?[J]. Hepatology, 2012, 56(4):1352-1360.
[7] NAKANUMA Y, UESAKA K, KAKUDA Y, et al. Intraductal papillary neoplasm of bile duct: updated clinicopathological characteristics and molecular and genetic alterations[J]. J Clin Med, 2020, 9(12):3991.
[8] ALBORES-SAAVEDRA J, ALCáNTRA-VAZQUEZ A, CRUZ-ORTIZ H, et al. The precursor lesions of invasive gallbladder carcinoma. Hyperplasia, atypical hyperplasia and carcinoma in situ[J]. Cancer, 1980, 45(5):919-927.
[9] MAZER L M, LOSADA H F, CHAUDHRY R M, et al. Tumor characteristics and survival analysis of incidental versus suspected gallbladder carcinoma[J]. J Gastrointest Surg, 2012, 16(7):1311-1317.
[10] BAL M M, RAMADWAR M, DEODHAR K, et al. Patho-logy of gallbladder carcinoma: current understanding and new perspectives[J]. Pathol Oncol Res, 2015, 21(3):509-525.
[11] ADSAY N V, KLIMSTRA D S. Benign and malignant tumors of the gallbladder and extrahepatic biliary tract - sciencedirect[M]//ODZE R D, GOLDBLUM J R. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. 2nd ed. Philadelphia: W.B.Saunders, 2009:845-875.
[12] DURSUN N, ESCALONA O T, ROA J C, et al. Mucinous carcinomas of the gallbladder: clinicopathologic analysis of 15 cases identified in 606 carcinomas[J]. Arch Pathol Lab Med, 2012, 136(11):1347-1358.
[13] VARDAMAN C, ALBORES-SAAVEDRA J. Clear cell carcinomas of the gallbladder and extrahepatic bile ducts[J]. Am J Surg Pathol, 1995, 19(1):91-99.
[14] KONISHI E, NAKASHIMA Y, SMYRK TC, et al. Clear cell carcinoid tumor of the gallbladder - a case without von Hippel-Lindau disease[J]. Arch Pathol Lab Med, 2003, 127(6):745-747.
[15] ROA J C, BASTURK O, ADSAY V. Dysplasia and carcinoma of the gallbladder: pathological evaluation, sampling, differential diagnosis and clinical implications[J]. Histopathology, 2021, 79(1):2-19.
[16] ROA J C, TAPIA O, CAKIR A, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas[J]. Modern Pathol, 2011, 24(8):1069-1078.
[17] TASKIN O C, AKKAS G, MEMIS B, et al. Sarcomatoid carcinomas of the gallbladder: clinicopathologic characteristics[J]. Virchows Arch, 2019, 475(1):59-66.
[18] RIZVI S, KHAN S A, HALLEMEIER C L, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2):95-111.
[19] ALBORES-SAAVEDRA J, CHABLé-MONTERO F, MéNDEZ-SáNCHEZ N, et al. Adenocarcinoma with pyloric gland phenotype of the extrahepatic bile ducts: a previously unrecognized and distinctive morphologic variant of extrahepatic bile duct carcinoma[J]. Hum Pathol, 2012, 43(12):2292-2298.
[20] LENDVAI G, SZEKERCZéS T, ILLYéS I, et al. Cholangiocarcinoma: classification, histopathology and molecular carcinogenesis[J]. Pathol Oncol Res, 2020, 26(1):3-15.
[21] NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9):1003-1010.
[22] KIM S J, AKITA M, SUNG Y N, et al. MDM2 amplification in intrahepatic cholangiocarcinomas: its relationship with large-duct type morphology and uncommon KRAS mutations[J]. Am J Surg Pathol, 2018, 42(4):512-521.
[23] LOUIS C, PAPOUTSOGLOU P, COULOUARN C. Molecular classification of cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2020, 36(2):57-62.
[24] PUJALS A, AMADDEO G, CASTAIN C, et al. BRAF V600E mutations in bile duct adenomas[J]. Hepatology, 2015, 61(1):403-405.
[25] PUJALS A, BIOULAC-SAGE P, CASTAIN C, et al. BRAF V600E mutational status in bile duct adenomas and hamartomas[J]. Histopathology, 2015, 67(4):562-567.
[26] SASAKI M, SATO Y, NAKANUMA Y. Bile duct ade-noma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma[J]. Histopathology, 2021, 78(2):310-320.
[27] ARNASON T, BORGER D R, CORLESS C, et al. Biliary adenofibroma of liver: morphology, tumor genetics, and outcomes in 6 cases[J]. Am J Surg Pathol, 2017, 41(4):499-505.
[28] GUPTA A, DIXON E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma[J]. Hepatobiliary Surg Nutr, 2017, 6(2):101-104.
[29] MOEINI A, HABER P K, SIA D. Cell of origin in biliary tract cancers and clinical implications[J]. JHEP Rep, 2021, 3(2):100226.
[30] MATSUKUMA K E, YEH M M. Update on the pathology of liver neoplasms[J]. Ann Diagn Pathol, 2019, 38:126-137.
[31] NAKANUMA Y, MIYATA T, UCHIDA T. Latest advances in the pathological understanding of cholangiocarcinomas[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(1):113-127.
[32] MONDACA S, RAZAVI P, XU C, et al. Genomic characterization of ERBB2-driven biliary cancer and a case of response to ado-trastuzumab emtansine[J]. JCO Precis Oncol,3:PO.19.00223.
[33] AISHIMA S, ODA Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type[J]. J Hepatobiliary Pancreat Sci, 2015, 22(2):94-100.
[34] AKITA M, SAWADA R, KOMATSU M, et al. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping[J]. Hum Pathol, 2021, 109:45-52.
[35] ROSS J S, WANG K, GAY L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing[J]. Oncologist, 2014, 19(3):235-242.
[36] LOWERY M A, PTASHKIN R, JORDAN E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention[J]. Clin Cancer Res, 2018, 24(17):4154-4161.
[37] STEINER P E, HIGGINSON J. Cholangiolocellular carcinoma of the liver[J]. Cancer, 1959, 12(4):753-759.
[38] NAKANUMA Y, SATO Y, IKEDA H, et al. Intrahepatic cholangiocarcinoma with predominant "ductal plate malformation" pattern: a new subtype[J]. Am J Surg Pathol, 2012, 36(11):1629-1635.
[39] NAULT J C, VILLANUEVA A. Biomarkers for hepatobiliary cancers[J]. Hepatology, 2021, 73(Suppl 1):115-127.
Options
Outlines

/

〈 〉